251 related articles for article (PubMed ID: 25714238)
1. Defining 'progression' and triggers for curative intervention during active surveillance.
Klotz L
Curr Opin Urol; 2015 May; 25(3):258-66. PubMed ID: 25714238
[TBL] [Abstract][Full Text] [Related]
2. Active surveillance for low-risk prostate cancer.
Klotz L
Curr Urol Rep; 2015 Apr; 16(4):24. PubMed ID: 25764118
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance for low-risk prostate cancer.
Klotz L
Curr Opin Urol; 2017 May; 27(3):225-230. PubMed ID: 28267056
[TBL] [Abstract][Full Text] [Related]
4. Active Surveillance for Prostate Cancer: How to Do It Right.
Garisto JD; Klotz L
Oncology (Williston Park); 2017 May; 31(5):333-40, 345. PubMed ID: 28512731
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
[TBL] [Abstract][Full Text] [Related]
6. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
[TBL] [Abstract][Full Text] [Related]
7. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
8. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
9. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
[TBL] [Abstract][Full Text] [Related]
10. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance: the Canadian experience.
Klotz L
Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
Klotz LH; Nam RK
Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
[TBL] [Abstract][Full Text] [Related]
13. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?
Tay KJ; Mendez M; Moul JW; Polascik TJ
Curr Opin Urol; 2015 May; 25(3):185-90. PubMed ID: 25768694
[TBL] [Abstract][Full Text] [Related]
14. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
15. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.
Klotz L
Nat Clin Pract Urol; 2005 Mar; 2(3):136-42; quiz 1 p following 149. PubMed ID: 16474710
[TBL] [Abstract][Full Text] [Related]
16. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
Klotz LH
Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
[TBL] [Abstract][Full Text] [Related]
19. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
20. Active surveillance and focal therapy for low-intermediate risk prostate cancer.
Klotz L
Transl Androl Urol; 2015 Jun; 4(3):342-54. PubMed ID: 26816834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
